AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/24/2026

1. INTC
2. DECK
3. META
4. AMD
5. INFY
6. UNP
7. RNG
8. ROL
9. GOOGL
10. URI

Go back to AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection
AbbVie (NYSE: ABBV) Delayed: 258.81 +1.89 (0.74%)
Previous Close $256.92    52 Week High $68.12 
Open $258.54    52 Week Low $50.71 
Day High $260.22    P/E 56.14 
Day Low $256.77    EPS $4.61 
Volume 2,353,669